Surmodics Statistics
Total Valuation
Surmodics has a market cap or net worth of $388.47 million. The enterprise value is $388.32 million.
Important Dates
The next estimated earnings date is Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Surmodics has 14.30 million shares outstanding. The number of shares has increased by 0.87% in one year.
| Current Share Class | 14.30M |
| Shares Outstanding | 14.30M |
| Shares Change (YoY) | +0.87% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 3.66% |
| Owned by Institutions (%) | 81.16% |
| Float | 12.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.20 |
| Forward PS | 3.13 |
| PB Ratio | 3.49 |
| P/TBV Ratio | 8.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.21 |
| EV / EBITDA | 55.33 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.91, with a Debt / Equity ratio of 0.29.
| Current Ratio | 3.91 |
| Quick Ratio | 2.88 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 3.72 |
| Debt / FCF | n/a |
| Interest Coverage | -0.41 |
Financial Efficiency
Return on equity (ROE) is -15.36% and return on invested capital (ROIC) is -0.61%.
| Return on Equity (ROE) | -15.36% |
| Return on Assets (ROA) | -0.52% |
| Return on Invested Capital (ROIC) | -0.61% |
| Return on Capital Employed (ROCE) | -0.96% |
| Revenue Per Employee | $310,542 |
| Profits Per Employee | -$45,314 |
| Employee Count | 389 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 1.84 |
Taxes
In the past 12 months, Surmodics has paid $2.94 million in taxes.
| Income Tax | 2.94M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.57% in the last 52 weeks. The beta is 1.31, so Surmodics's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | -27.57% |
| 50-Day Moving Average | 30.74 |
| 200-Day Moving Average | 31.28 |
| Relative Strength Index (RSI) | 29.54 |
| Average Volume (20 Days) | 87,388 |
Short Selling Information
The latest short interest is 400,421, so 2.80% of the outstanding shares have been sold short.
| Short Interest | 400,421 |
| Short Previous Month | 325,821 |
| Short % of Shares Out | 2.80% |
| Short % of Float | 3.26% |
| Short Ratio (days to cover) | 3.10 |
Income Statement
In the last 12 months, Surmodics had revenue of $120.80 million and -$17.63 million in losses. Loss per share was -$1.24.
| Revenue | 120.80M |
| Gross Profit | 92.07M |
| Operating Income | -1.45M |
| Pretax Income | -14.69M |
| Net Income | -17.63M |
| EBITDA | 7.02M |
| EBIT | -1.45M |
| Loss Per Share | -$1.24 |
Full Income StatementBalance Sheet
The company has $32.73 million in cash and $32.58 million in debt, giving a net cash position of $146,000 or $0.01 per share.
| Cash & Cash Equivalents | 32.73M |
| Total Debt | 32.58M |
| Net Cash | 146,000 |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | 111.31M |
| Book Value Per Share | 7.78 |
| Working Capital | 56.55M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.88 million and capital expenditures -$1.66 million, giving a free cash flow of -$3.55 million.
| Operating Cash Flow | -1.88M |
| Capital Expenditures | -1.66M |
| Free Cash Flow | -3.55M |
| FCF Per Share | -$0.25 |
Full Cash Flow StatementMargins
Gross margin is 76.22%, with operating and profit margins of -1.20% and -14.59%.
| Gross Margin | 76.22% |
| Operating Margin | -1.20% |
| Pretax Margin | -12.16% |
| Profit Margin | -14.59% |
| EBITDA Margin | 5.81% |
| EBIT Margin | -1.20% |
| FCF Margin | n/a |
Dividends & Yields
Surmodics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.87% |
| Shareholder Yield | -0.87% |
| Earnings Yield | -4.54% |
| FCF Yield | -0.91% |
Analyst Forecast
The average price target for Surmodics is $43.00, which is 58.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $43.00 |
| Price Target Difference | 58.26% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 7, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 7, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Surmodics has an Altman Z-Score of 6.8 and a Piotroski F-Score of 2.
| Altman Z-Score | 6.8 |
| Piotroski F-Score | 2 |
